

# LONDON ONCOLOGY CLINICAL TRIALS

## OESOPHAGEAL CANCER STUDIES

Disease Area	Treatment	Phase	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principle Investigator	Contact	Inclusion/Exclusion
Barrett's Oesophagus	Prevention	NA	Interventional	ChOPIN	Chemoprevention of premalignant intestinal neoplasia (ChOPIN) incorporating inherited predisposition of neoplasia (IPOD) analysis of genomic DNA from AspECT and BOSS clinical trials. It also incorporates patients undergoing genomic assessment independent of the AspECT and BOSS trials.	Yes	6858	Prof Janusz Jankowski	King's College Hospital NHS Foundation Trust	King's College Hospital			<a href="http://www.cancerresearchuk.org/about-cancer/trials/a-study-to-find-out-why-certain-people-develop-oesophageal-cancer-chopin">http://www.cancerresearchuk.org/about-cancer/trials/a-study-to-find-out-why-certain-people-develop-oesophageal-cancer-chopin</a>
									Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	<a href="mailto:David.Cunningham@rmh.nhs.uk">David.Cunningham@rmh.nhs.uk</a>	
									Lewisham and Greenwich NHS Trust	Queen Elizabeth Woolwich University Hospital Lewisham			
	Screening	NA	Interventional	Evaluation of a NonEndoscopic Device for Barrett's Oesophagus - BEST 2	Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge) for Barrett's Esophagus Screening in a Case-Control Study	Yes	9461	Dr Rebecca Fitzgerald	North West London Hospitals NHS Trust	St Mark's Hospital			<a href="http://www.cancerresearchuk.org/about-cancer/trials/a-study-to-see-how-well-a-new-way-screening-for-barretts-oesophagus-works-best2">http://www.cancerresearchuk.org/about-cancer/trials/a-study-to-see-how-well-a-new-way-screening-for-barretts-oesophagus-works-best2</a>
		NA	Interventional	Multiparametric MRI for Oesophageal Cancer (MIMOSA)	Multiparametric Magnetic Resonance Imaging for Oesophageal cancer assessment: a pilot study	Yes	15993	Dr Vicky Goh	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Vicky Goh	<a href="mailto:adrian.green@gstt.nhs.uk">adrian.green@gstt.nhs.uk</a>	
	Screening	NA	Observational	BOOST	Barrett's oesophagus and optical biopsy using elastic scattering spectroscopy to target high risk lesions (BOOST)	Yes	4363	Dr Sarah Jevons	University College London Hospitals NHS Foundation Trust	University College London Hospital	Prof Laurence Lovat	<a href="mailto:CCTU.admin@uclh.nhs.uk">CCTU.admin@uclh.nhs.uk</a>	<a href="https://ukcrn.nhs.uk/trials/trial-details/trialNumber=ISRCTN58235288">https://ukcrn.nhs.uk/trials/trial-details/trialNumber=ISRCTN58235288</a>
Treatment	NA	Interventional	UK HALO Registry	A National Registry for HALO360 and HALO90 Radiofrequency Ablation of Barretts Columnar Lined Oesophagus	No		Prof Laurence Lovat	Guy's and St Thomas' NHS Foundation Trust	St Thomas' Hospital	Dr Jason Dunn	<a href="mailto:askOHCT@gstt.nhs.uk">askOHCT@gstt.nhs.uk</a>	<a href="http://www.barretts-oesophagus.co.uk/patients_UK_National_HALO_patient_registry.htm">http://www.barretts-oesophagus.co.uk/patients_UK_National_HALO_patient_registry.htm</a>	
								Imperial College NHS Healthcare Trust	St Mary's Hospital	Dr Jonathan Hoare	<a href="mailto:Jonathan.Hoare@imperial.nhs.uk">Jonathan.Hoare@imperial.nhs.uk</a>		
								University College London Hospitals NHS Foundation Trust	University College London Hospital	Prof Laurence Lovat	<a href="mailto:CCTU.admin@uclh.nhs.uk">CCTU.admin@uclh.nhs.uk</a>		
Patients referred for a GI endoscopy or undergoing GI resection for cancer	Screening	NA	Observational	Non-invasive diagnostic testing for Gastro-intestinal disease	Non-invasive testing for the diagnosis and assessment of Gastro-intestinal disease	Yes	18063	Prof George Hanna	Imperial College NHS Healthcare Trust	St Mary's Hospital	Prof George Hanna	<a href="mailto:Gillian.Hornzee@imperial.nhs.uk">Gillian.Hornzee@imperial.nhs.uk</a>	<a href="http://public-odp.nhs.uk/QuAJAX2fc/openDoc.htm?document=CRNCC_Use%20rs%20Find%20A%20Clinical%20Research%20Study.qvw&amp;sheet=SH75&amp;bookmark=Document\BM02&amp;select=LB572,=StudyID=20545">http://public-odp.nhs.uk/QuAJAX2fc/openDoc.htm?document=CRNCC_Use%20rs%20Find%20A%20Clinical%20Research%20Study.qvw&amp;sheet=SH75&amp;bookmark=Document\BM02&amp;select=LB572,=StudyID=20545</a>
										NHS BRENT CCG			
										NHS EALING CCG			
										NHS HAMMERSMITH AND FULHAM CCG			
										NHS HILLINGDON CCG			
Neoadjuvant	Neoadjuvant	II	Interventional	NeoSCOPE: Neoadjuvant - Study of Chemoradiotherapy in Oesophageal Cancer	A randomised Phase II study of two preoperative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer.	Yes	13764	Dr Tom Crosby	North West London Hospitals NHS Trust	St Mark's Hospital			
	Preoperative Cohort Study	NA	Observational	Preoperative Iron Deficiency & Anaemia in Oesophagogastric Cancer	The Management of Preoperative Iron Deficiency and Anaemia in Patients with Oesophagogastric cancer, undergoing the Curative Surgical Treatment Pathway: A Prospective Observational Cohort Study.	Yes	18908	Mr James Gossage	Guy's and St Thomas' NHS Foundation Trust	St Thomas' Hospital	Ms Orla Hynes	<a href="mailto:Orla.Hynes@gstt.nhs.uk">Orla.Hynes@gstt.nhs.uk</a>	
	Pre-Surgical	Pilot	Interventional	Pre-EMPT	Prehabilitation in patients with oEsophageal Malignancies undergoing Peri-operative Treatment	No		Mr James Gossage	Guy's and St Thomas' NHS Foundation Trust	St Thomas' Hospital		<a href="mailto:askOHCT@gstt.nhs.uk">askOHCT@gstt.nhs.uk</a>	
		NA	Observational	HRQL after Upper GI Surgery	Health-related Quality of Life after Surgery for Upper Gastrointestinal Tumours	Yes	14702	Prof Jesper Lagergren	Guy's and St Thomas' NHS Foundation Trust		Prof Jesper Lagergren	<a href="mailto:askOHCT@gstt.nhs.uk">askOHCT@gstt.nhs.uk</a>	
	IV	Observational		OCCAMS	Oesophageal Cancer Clinical and Molecular Stratification Study (OCCAMS) - A Multicentre Study to Determine Predictive and Prognostic Biomarkers and Therapeutic Targets for Oesophageal and Junctional Adenocarcinoma including Whole Genome Sequencing	Yes	8880	Dr Rebecca Fitzgerald	Imperial College NHS Healthcare Trust	St Mary's Hospital	Prof George Hanna	<a href="mailto:Gillian.Hornzee@imperial.nhs.uk">Gillian.Hornzee@imperial.nhs.uk</a>	<a href="http://www.cancerresearchuk.org/about-cancer/trials/a-study-looking-cell-changes-pre-cancer-and-cancer-where-food-pipe-meets-stomach-occams">http://www.cancerresearchuk.org/about-cancer/trials/a-study-looking-cell-changes-pre-cancer-and-cancer-where-food-pipe-meets-stomach-occams</a>
									Guy's and St Thomas' NHS Foundation Trust	St Thomas' Hospital		<a href="mailto:askOHCT@gstt.nhs.uk">askOHCT@gstt.nhs.uk</a>	
									Barking, Havering and Redbridge University Hospitals NHS Trust				
								University College London Hospitals NHS Foundation Trust	University College London Hospital		<a href="mailto:CCTU.admin@uclh.nhs.uk">CCTU.admin@uclh.nhs.uk</a>		
post-surgical	NA	Observational	Patient Experience of Swallowing Following Oesophageal Surgery	Patient Experience of Swallowing Following Oesophageal Surgery	No		Dr Theresa Wiseman	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Theresa Wiseman	<a href="mailto:Theresa.Wiseman@rmh.nhs.uk">Theresa.Wiseman@rmh.nhs.uk</a>		
1st line	III	Interventional	Neo-AEGIS	Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (MAGIC regimen) vs. neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the oesophagus and oesophago-gastric junction.	Yes	18094	Mr Shaun Preston	Imperial College NHS Healthcare Trust	St Mary's Hospital	Prof George Hanna	<a href="mailto:Gillian.Hornzee@imperial.nhs.uk">Gillian.Hornzee@imperial.nhs.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT01726452">https://clinicaltrials.gov/ct2/show/NCT01726452</a>	
Adjuvant	III	Interventional	CheckMate 577	A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer	No		Dr Ian Chau	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Ian Chau			
								Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital		<a href="https://clinicaltrials.gov/ct2/show/NCT02743494">https://clinicaltrials.gov/ct2/show/NCT02743494</a>		

# LONDON ONCOLOGY CLINICAL TRIALS

## OESOPHAGEAL CANCER STUDIES

Disease Area	Treatment	Phase	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principle Investigator	Contact	Inclusion/Exclusion
Oesophageal cancer									University College London Hospital	Univeristy College London Hospital			
	Advanced 1st line	III	Interventional	GAMMA-1	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Yes	27513	Prof David Cunningham	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	<a href="mailto:David.Cunningham@rmh.nhs.uk">David.Cunningham@rmh.nhs.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT02545504">https://clinicaltrials.gov/ct2/show/NCT02545504</a>
		University College London Hospitals NHS Foundation Trust							Univeristy College London Hospital		<a href="mailto:CCTU.admin@uclh.nhs.uk">CCTU.admin@uclh.nhs.uk</a>		
		I/II	Interventional	FACING	A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)	Yes	11668	Prof T R J Evans	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital		<a href="mailto:askOHCT@gstt.nhs.uk">askOHCT@gstt.nhs.uk</a>	<a href="http://www.cancerresearchuk.org/about-cancer/trials/a-trial-of-azd4547-with-cisplatin-and-capecitabine-for-advanced-">http://www.cancerresearchuk.org/about-cancer/trials/a-trial-of-azd4547-with-cisplatin-and-capecitabine-for-advanced-</a>
		Imperial College NHS Healthcare Trust	St Mary's Hospital		<a href="mailto:Gillian.Hornzee@imperial.nhs.uk">Gillian.Hornzee@imperial.nhs.uk</a>								
	III	Interventional	G02	Alternative chemotherapy for frail or elderly patients with advanced gastric or oesophageal cancer	Yes	15037	Prof Matt Seymour	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Nick Maisey	<a href="mailto:askOHCT@gstt.nhs.uk">askOHCT@gstt.nhs.uk</a>		
								Imperial College NHS Healthcare Trust	St Mary's Hospital	Dr Danielle Power	<a href="mailto:Gillian.Hornzee@imperial.nhs.uk">Gillian.Hornzee@imperial.nhs.uk</a>	<a href="https://ukctg.nihr.ac.uk/trials/trial-details/trial-details?trialNumber=ISRCTN44687907">https://ukctg.nihr.ac.uk/trials/trial-details/trial-</a>	
								Barking, Havering and Redbridge University Hospitals NHS Trust				<a href="https://ukctg.nihr.ac.uk/trials/trial-details?trialNumber=ISRCTN44687907">details?trialNumber=ISRCTN44687907</a>	
	III	Interventional	NCRN366: Rilotumumab + ECX in 1st line c-Met Gastric or Gastroesophageal Junction Adenocarcinoma	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in c-Met Enriched Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Yes	12906	Prof David Cunningham	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	<a href="mailto:David.Cunningham@rmh.nhs.uk">David.Cunningham@rmh.nhs.uk</a>		
								Guy's and St Thomas' NHS Foundation Trust		Dr Nick Maisey	<a href="mailto:askOHCT@gstt.nhs.uk">askOHCT@gstt.nhs.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT01697072">https://clinicaltrials.gov/ct2/show/NCT01697072</a>	

# LONDON ONCOLOGY CLINICAL TRIALS

## OESOPHAGEAL CANCER STUDIES

Disease Area	Treatment	Phase	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principle Investigator	Contact	Inclusion/Exclusion
	1st line Maintenance	III	Interventional	PLATFORM	Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial (PLATFORM Trial)	Yes	18432	Prof David Cunningham	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	<a href="mailto:Bijal.Patel@rmh.nhs.uk">Bijal.Patel@rmh.nhs.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT02678182">https://clinicaltrials.gov/ct2/show/NCT02678182</a>
									Royal Free London NHS Foundation Trust	Royal Free Hospital			
		III	Interventional	JAVELIN Gastric 100	A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction	No			Barts Health NHS Trust	St Bartholomew's Hospital	Dr David Propper	<a href="mailto:sue.mccartney@qmul.ac.uk">sue.mccartney@qmul.ac.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT02625610">https://clinicaltrials.gov/ct2/show/NCT02625610</a>
									University College London Hospitals NHS Foundation Trust	University College London Hospital	Kai-Keen Shiu	<a href="mailto:christopher.wanstall@uclh.nhs.uk">christopher.wanstall@uclh.nhs.uk</a>	
	2nd line	III	Interventional	NCRN - 3258 BBI608 plus Weekly Paclitaxel in Gastric and GEJ Adenocarcinoma (216525)	A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of BBI608 plus Weekly Paclitaxel vs. Placebo plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma	Yes	18109	Dr Naureen Starling	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Dr Naureen Starling	<a href="mailto:Naureen.Starling@rmh.nhs.uk">Naureen.Starling@rmh.nhs.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/study/NCT02178956?show_loc=cs=Y#locn">https://clinicaltrials.gov/ct2/show/study/NCT02178956?show_loc=cs=Y#locn</a>
	Advanced 3rd line	II	Interventional	KEYNOTE - 180 / CANC 5428	A phase II Study of Pembrolizumab Monotherapy in Third-Line Previously Treated Subjects with Advanced/ Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced / Metastatic Siewert Type I Adenocarcinoma of the Esophagogastric Junction	Yes			University College London Hospitals NHS Foundation Trust	University College London Hospital		<a href="mailto:CCTU.admin@uclh.nhs.uk">CCTU.admin@uclh.nhs.uk</a>	<a href="https://clinicaltrials.gov/show/NCT02864381">https://clinicaltrials.gov/show/NCT02864381</a>
	Advanced - Supportive Care	III	Interventional	ROCS Study	Palliative Radiotherapy in Addition to Self-expanding Metal Stent for Improving Dysphagia and Survival in Advanced Oesophageal Cancer: ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study.	Yes	14309	Dr Douglas Adamson	Basildon and Thurrock University Hospital NHS Foundation Trust				<a href="https://clinicaltrials.gov/ct2/show/NCT01915693">https://clinicaltrials.gov/ct2/show/NCT01915693</a>
Southend University Hospital NHS Foundation Trust													
Imperial College Healthcare NHS Trust									St Mary's Hospital		<a href="mailto:Gillian.Hornzee@imperial.nhs.uk">Gillian.Hornzee@imperial.nhs.uk</a>		
Her2+	1st line	II/III	Interventional	ST03	A Randomised Phase II/III trial of Peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and (in selected centres) A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas.	Yes	1752	Prof David Cunningham	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Nick Maisey	<a href="mailto:askOHCT@gstt.nhs.uk">askOHCT@gstt.nhs.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT00450203">https://clinicaltrials.gov/ct2/show/NCT00450203</a>
									Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	<a href="mailto:David.Cunningham@rmh.nhs.uk">David.Cunningham@rmh.nhs.uk</a>	
									Royal Free London NHS Foundation Trust				
									St George's University Hospitals NHS Foundation Trust	St George's University Hospital			
									Bart's Health NHS Trust	St Bartholomew's Hospital	Dr Sarah Slater		
									Barking, Havering and Redbridge University Hospitals NHS Trust	Queen's Hospital	Dr Sherif Raouf		
									Imperial College NHS Healthcare Trust	St Mary's Hospital	Dr Danielle Power	<a href="mailto:Gillian.Hornzee@imperial.nhs.uk">Gillian.Hornzee@imperial.nhs.uk</a>	
Advanced 2nd line	II/III	Interventional	NCRN369: GATSBY TDM1 vs taxane in previously treated advanced HER2+ gastric ca	A randomized, multicenter, adaptive phase II-III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (docetaxel or paclitaxel) in patients with previously treated locally advanced or metastatic HER2-positive gastric cancer, including adenocarcinoma of the gastroesophageal junction	Yes	12204	Dr Was Mansoor	Imperial College NHS Healthcare Trust			<a href="http://www.cancerresearchuk.org/about-cancer/trials/a-trial-looking-at-tdm1-for-advanced-her2-positive-cancer-of-the-stomach-or-goj-cancer">http://www.cancerresearchuk.org/about-cancer/trials/a-trial-looking-at-tdm1-for-advanced-her2-positive-cancer-of-the-stomach-or-goj-cancer</a>		
Advanced 2nd line	II	Interventional	IMPACT - MM-111	Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy	No		Dr David Watkins	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Dr David Watkins		<a href="https://clinicaltrials.gov/ct2/show/NCT01774851">https://clinicaltrials.gov/ct2/show/NCT01774851</a>	
MET+	Advanced 2nd line	II	Interventional	NCRN - 2265 MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma	A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG 337 in Subjects with MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET	Yes	15315	Dr Anne Thomas	Guy's and St Thomas' NHS Foundation Trust			<a href="mailto:askOHCT@gstt.nhs.uk">askOHCT@gstt.nhs.uk</a>	<a href="http://www.cancerresearchuk.org/about-cancer/trials/a-trial-of-amg337-for-advanced-solid-tumours-that-have-large-number-of-copies-of-gene">http://www.cancerresearchuk.org/about-cancer/trials/a-trial-of-amg337-for-advanced-solid-tumours-that-have-large-number-of-copies-of-gene</a>
									Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	<a href="mailto:David.Cunningham@rmh.nhs.uk">David.Cunningham@rmh.nhs.uk</a>	

# LONDON ONCOLOGY CLINICAL TRIALS

## OESOPHAGEAL CANCER STUDIES

Disease Area	Treatment	Phase	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principle Investigator	Contact	Inclusion/Exclusion
					Amplified Solid Tumours				East and North Hertfordshire NHS Trust	Mount Vernon Cancer Centre		<a href="mailto:crrtmountvernon@gmail.com">crrtmountvernon@gmail.com</a>	<a href="#">called-met</a>
c-MYC and HER2 amplified	2nd line+	II	Interventional	iMYC	Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma (iMYC)	No		Dr Ian Chau	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Ian Chau	<a href="mailto:yemong.to@rmh.nhs.uk">yemong.to@rmh.nhs.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT02884453">https://clinicaltrials.gov/ct2/show/NCT02884453</a>
FGFR1/2 Amplified Gastric, oesophageal, breast or SCC of lung cancer	Advanced	II	Interventional	Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours	Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours	No		Prof David Cunningham	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	<a href="mailto:angela.gillbanks@rmh.nhs.uk">angela.gillbanks@rmh.nhs.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT01795768?term=azd4547&amp;rank=7">https://clinicaltrials.gov/ct2/show/NCT01795768?term=azd4547&amp;rank=7</a>
									Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Nick Maisey	<a href="mailto:askOHCT@gstt.nhs.uk">askOHCT@gstt.nhs.uk</a>	
Solid Tumours	Advanced	I/II	Interventional	NCRN - 2808 CheckMate032 Nivolumab combined with Ipilimumab in Solid Tumours	CheckMate032: A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors	Yes	15842	Prof Jeff Evans	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Dr Ian Chau	<a href="mailto:ian.Chau@rmh.nhs.uk">ian.Chau@rmh.nhs.uk</a>	<a href="http://www.cancerresearchuk.org/about-cancer/trials/a-trial-nivolumab-ipilimumab-people-with-solid-tumours-that-have-spread">http://www.cancerresearchuk.org/about-cancer/trials/a-trial-nivolumab-ipilimumab-people-with-solid-tumours-that-have-spread</a>
		I/II	Interventional	NCRN - 2888 MEDI4736 in Advanced Solid Tumours	A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors	Yes	15886	Prof David Cunningham	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	<a href="mailto:David.Cunningham@rmh.nhs.uk">David.Cunningham@rmh.nhs.uk</a>	
		Ib	Interventional	CANC 5088	A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	No		Dr. Juanita S Lopez	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Dr. Juanita S Lopez	<a href="mailto:mahesha.ganegoda@icr.ac.uk">mahesha.ganegoda@icr.ac.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT02722954">https://clinicaltrials.gov/ct2/show/NCT02722954</a>
		I	Interventional	CANC 5659 (REFMAL 444)	A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4Antibody) in Subjects with Advanced Solid Tumors	No			Barts Health NHS Trust	St Bartholomew's Hospital			
									University College London Hospitals NHS Foundation Trust	University College London Hospital	Dr Rebecca Kristeleit	<a href="mailto:r.kristeleit@ucl.ac.uk">r.kristeleit@ucl.ac.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT02261220">https://clinicaltrials.gov/ct2/show/NCT02261220</a>
									Royal Free London NHS Foundation Trust	Royal Free Hospital			
									Sarah Cannon Research Institute UK			<a href="#">SCRI Referral Template</a>	

# LONDON ONCOLOGY CLINICAL TRIALS

## OESOPHAGEAL CANCER STUDIES

Disease Area	Treatment	Phase	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principle Investigator	Contact	Inclusion/Exclusion
Patients with anaemia undergoing major open abdominal surgery	Supportive Care	III	Interventional	PREVENTT	A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose with placebo in patients with anaemia undergoing major open abdominal surgery	Yes	13680	Dr Toby Richards	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Dr Ravishankar Raobaikady	<a href="mailto:Ravishankar.Raobaikady@rmh.nhs.uk">Ravishankar.Raobaikady@rmh.nhs.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT01692418">https://clinicaltrials.gov/ct2/show/NCT01692418</a>
									Hillingdon Hospitals NHS Foundation Trust	Hillingdon Hospital	Dr Cheryl Messer		
									Bart's Health NHS Trust	Royal London Hospital	Dr Shubha Allard	<a href="mailto:Shubha.Allard@bartshealth.nhs.uk">Shubha.Allard@bartshealth.nhs.uk</a>	
									Royal Free London NHS Foundation Trust	Royal Free Hospital	Dr Susan Mallett		
									King's College Hospital	King's College Hospital	Dr Tim Hughes		
									University College London Hospitals NHS Foundation Trust	University College London Hospital	Dr Khaled Dawas	<a href="mailto:CCTU.admin@uclh.nhs.uk">CCTU.admin@uclh.nhs.uk</a>	
									Imperial College Healthcare NHS Trust	St Mary's Hospital	Dr Asela Dharmadasa	<a href="mailto:Gillian.Hornzee@imperial.nhs.uk">Gillian.Hornzee@imperial.nhs.uk</a>	
									Imperial College Healthcare NHS Trust	Charing Cross Hospital	Dr Asela Dharmadasa	<a href="mailto:susan.mcinerney@imperial.nhs.uk">susan.mcinerney@imperial.nhs.uk</a>	
									Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Jugdeep Dhesi	<a href="mailto:askOHCT@gstt.nhs.uk">askOHCT@gstt.nhs.uk</a>	
Venous Thromboembolism	Supportive Care	III	Interventional	Select-D	Select-d: Anticoagulation Therapy in SELECTed Cancer Patients at Risk of Recurrence of Venous Thromboembolism	Yes	14296	Prof Annie Young	Imperial College Healthcare NHS Trust	Charing Cross Hospital	Dr Danielle Power	<a href="mailto:Cathy.Maclean@imperial.nhs.uk">Cathy.Maclean@imperial.nhs.uk</a>	<a href="http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-comparing-blood-thinning-injection-with-blood-thinning-tablet-for-people-with-cancer-who-have-blood-clot-select-d">http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-comparing-blood-thinning-injection-with-blood-thinning-tablet-for-people-with-cancer-who-have-blood-clot-select-d</a>
										Hammersmith Hospital		<a href="mailto:Hammersmith.Cancertrials@imperial.nhs.uk">Hammersmith.Cancertrials@imperial.nhs.uk</a>	
										St Mary's Hospital London		<a href="mailto:Gillian.Hornzee@imperial.nhs.uk">Gillian.Hornzee@imperial.nhs.uk</a>	
									Chelsea & Westminster Hospital NHS Foundation Trust	Chelsea & Westminster Hospital	Dr Tom Newsom-Davis		
									London North West Hospital NHS Trust	Ealing Hospital	Dr Conrad Lewanski		
									The Hillingdon Hospitals NHS Foundation Trust	Hillingdon Hospital	Dr Amy Guppy		
									The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Ian Chau	<a href="mailto:Ian.Chau@rmh.nhs.uk">Ian.Chau@rmh.nhs.uk</a>	
									East and North Hertfordshire NHS Trust	Mount Vernon Cancer Centre		<a href="mailto:ctrmountvernon@gmail.com">ctrmountvernon@gmail.com</a>	
All cancers receiving chemo	Delivery of treatment	III	Interventional	Cancer And Venous Access (CAVA)	Cancer and Venous Access (CAVA) - A randomised controlled trial with associated qualitative research of venous access devices for the delivery of long-term chemotherapy	Yes	14600	Prof Jon Moss	Imperial College Healthcare NHS Trust	Hammersmith Hospital	Dr Alison Graham	<a href="mailto:Hammersmith.Cancertrials@imperial.nhs.uk">Hammersmith.Cancertrials@imperial.nhs.uk</a>	<a href="http://www.isrctn.com/ISRCTN44504648">http://www.isrctn.com/ISRCTN44504648</a>
Patients who have undergone surgery for Oesophagogastric Cancer	Pilot	NA	Observational	PROGRESS	PROGRESS : Identifying Prognostic and Predictive Biomarkers in Oesophagogastric Cancer : GSTT/Royal Marsden translational research collaboration	Yes	19210	Prof David Cunningham	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	<a href="mailto:David.Cunningham@rmh.nhs.uk">David.Cunningham@rmh.nhs.uk</a>	
Oesophageal	Pilot	NA	Observational	Microarray	Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer	No		Prof David Cunningham	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	<a href="mailto:David.Cunningham@rmh.nhs.uk">David.Cunningham@rmh.nhs.uk</a>	<a href="https://clinicaltrials.gov/ct2/show/NCT00220077">https://clinicaltrials.gov/ct2/show/NCT00220077</a>
Neuroendocrine tumours	Pilot	NA	Observational	IMMUNET	Systematic Evaluation of the Immune Environment of Neuroendocrine Tumours	Yes	20545	Prof Tim Meyer	Royal Free London NHS Foundation Trust	Royal Free Hospital	Prof Tim Meyer	<a href="mailto:melissa.back@nhs.net">melissa.back@nhs.net</a>	<a href="http://public-odp.nihr.ac.uk/QvAJAZZfc/open doc.htm?document=CRNCC_Users%2FFind%20A%20Clinical%20Research%20Study.qvw&amp;sheet=SH75&amp;bookmark=Document\BM02&amp;select=LB572_StudyID=20545">http://public-odp.nihr.ac.uk/QvAJAZZfc/open doc.htm?document=CRNCC_Users%2FFind%20A%20Clinical%20Research%20Study.qvw&amp;sheet=SH75&amp;bookmark=Document\BM02&amp;select=LB572_StudyID=20545</a>
	Pilot	NA							King's College London	King's College London			
	Pilot	NA	Observational	Characterisation of CTCs and cDNA in patients with cancer	Characterisation of circulating tumour cells and cDNA in patients with cancer	Yes	14929	Prof Tim Meyer	Royal Free London NHS Foundation Trust	Royal Free Hospital	Prof Tim Meyer		